News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
564,233 Results
Type
Article (40978)
Company Profile (83)
Press Release (523165)
Multimedia
Podcasts (70)
Webinars (15)
Section
Business (152224)
Career Advice (2448)
Deals (27810)
Drug Delivery (110)
Drug Development (73160)
Employer Resources (141)
FDA (13831)
Job Trends (12263)
News (272118)
Policy (27121)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2543)
Academic (1)
Accelerated approval (30)
Adcomms (29)
Allergies (133)
Alliances (38454)
ALS (170)
Alzheimer's disease (1666)
Antibody-drug conjugate (ADC) (298)
Approvals (14056)
Artificial intelligence (468)
Autoimmune disease (137)
Automation (34)
Bankruptcy (310)
Best Places to Work (9994)
BIOSECURE Act (16)
Biosimilars (168)
Biotechnology (61)
Bladder cancer (152)
Brain cancer (55)
Breast cancer (603)
Cancer (4540)
Cardiovascular disease (395)
Career advice (2073)
Career pathing (36)
CAR-T (258)
CDC (42)
Cell therapy (686)
Cervical cancer (28)
Clinical research (62846)
Collaboration (1443)
Company closure (4)
Compensation (600)
Complete response letters (59)
COVID-19 (2579)
CRISPR (80)
C-suite (858)
Cystic fibrosis (123)
Data (5926)
Decentralized trials (2)
Denatured (10)
Depression (139)
Diabetes (479)
Diagnostics (6000)
Digital health (37)
Diversity (8)
Diversity, equity & inclusion (39)
Drug discovery (217)
Drug pricing (171)
Drug shortages (25)
Duchenne muscular dystrophy (226)
Earnings (57741)
Editorial (54)
Employer branding (18)
Employer resources (133)
Events (78341)
Executive appointments (975)
FDA (16695)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (21)
Funding (1261)
Gene editing (176)
Generative AI (41)
Gene therapy (585)
GLP-1 (943)
Government (4353)
Grass and pollen (7)
Guidances (378)
Healthcare (16032)
HIV (56)
Huntington's disease (45)
IgA nephropathy (81)
Immunology and inflammation (260)
Immuno-oncology (54)
Indications (98)
Infectious disease (2836)
Inflammatory bowel disease (177)
Inflation Reduction Act (13)
Influenza (108)
Intellectual property (227)
Interviews (526)
IPO (12622)
IRA (48)
Job creations (2586)
Job search strategy (1674)
JPM (55)
Kidney cancer (17)
Labor market (58)
Layoffs (503)
Leadership (37)
Legal (5775)
Liver cancer (90)
Longevity (10)
Lung cancer (644)
Lymphoma (358)
Machine learning (34)
Management (51)
Manufacturing (665)
MASH (175)
Medical device (10890)
Medtech (10934)
Mergers & acquisitions (16139)
Metabolic disorders (1229)
Multiple sclerosis (155)
NASH (23)
Neurodegenerative disease (315)
Neuropsychiatric disorders (92)
Neuroscience (2873)
Neurotech (1)
NextGen: Class of 2026 (5532)
Non-profit (4005)
Now hiring (54)
Obesity (562)
Opinion (265)
Ovarian cancer (159)
Pain (191)
Pancreatic cancer (213)
Parkinson's disease (269)
Partnered (28)
Patents (457)
Patient recruitment (459)
Peanut (49)
People (52340)
Pharmaceutical (19)
Pharmacy benefit managers (18)
Phase 1 (19343)
Phase 2 (27613)
Phase 3 (21091)
Pipeline (4932)
Policy (266)
Postmarket research (2313)
Preclinical (7892)
Press Release (54)
Prostate cancer (225)
Psychedelics (54)
Radiopharmaceuticals (244)
Rare diseases (811)
Real estate (4132)
Recruiting (60)
Regulatory (21106)
Reports (30)
Research institute (2165)
Resumes & cover letters (358)
Rett syndrome (26)
RNA editing (15)
RSV (68)
Schizophrenia (149)
Series A (207)
Series B (164)
Service/supplier (3)
Sickle cell disease (94)
Special edition (17)
Spinal muscular atrophy (155)
Sponsored (37)
Startups (2770)
State (2)
Stomach cancer (18)
Supply chain (89)
Tariffs (72)
The Weekly (59)
Vaccines (926)
Venture capital (81)
Weight loss (374)
Women's health (70)
Worklife (19)
Date
Today (123)
Last 7 days (515)
Last 30 days (1932)
Last 365 days (26266)
2026 (2722)
2025 (26495)
2024 (30546)
2023 (34098)
2022 (44528)
2021 (47766)
2020 (46282)
2019 (39628)
2018 (30032)
2017 (26947)
2016 (25616)
2015 (29987)
2014 (22450)
2013 (18242)
2012 (19478)
2011 (20510)
2010 (18104)
Location
Africa (734)
Alabama (75)
Alaska (4)
Arizona (207)
Arkansas (11)
Asia (34866)
Australia (7246)
California (9220)
Canada (2951)
China (1015)
Colorado (394)
Connecticut (376)
Delaware (307)
Europe (78151)
Florida (1488)
Georgia (295)
Hawaii (1)
Idaho (52)
Illinois (769)
India (59)
Indiana (447)
Iowa (17)
Japan (395)
Kansas (110)
Kentucky (29)
Louisiana (24)
Maine (57)
Maryland (1203)
Massachusetts (6433)
Michigan (282)
Minnesota (472)
Mississippi (4)
Missouri (118)
Montana (25)
Nebraska (24)
Nevada (107)
New Hampshire (73)
New Jersey (2673)
New Mexico (21)
New York (2525)
North Carolina (1172)
North Dakota (6)
Northern California (4429)
Ohio (270)
Oklahoma (10)
Oregon (30)
Pennsylvania (1916)
Puerto Rico (23)
Rhode Island (36)
South America (996)
South Carolina (60)
South Dakota (1)
Southern California (3698)
Tennessee (142)
Texas (1516)
United States (33267)
Utah (305)
Vermont (1)
Virginia (228)
Washington D.C. (65)
Washington State (783)
West Virginia (4)
Wisconsin (85)
Wyoming (2)
564,233 Results for "ibio formerly known as ibiopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Metabolic disorders
Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath
The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according to RBC Capital.
October 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
December 23, 2025
·
9 min read
Press Releases
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
November 13, 2025
·
16 min read
Press Releases
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
November 11, 2025
·
4 min read
Press Releases
Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
September 12, 2025
·
4 min read
Press Releases
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
January 12, 2026
·
2 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
iBio Accelerates Transformation to AI-Powered Biotech
BRYAN, Texas and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization
November 10, 2022
·
7 min read
Cancer
JPM26: AbbVie Seeks Respect for Oncology Pipeline Following RemeGen Buy
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
January 14, 2026
·
2 min read
·
Heather McKenzie
1 of 56,424
Next
